Pomerantz LLP Advises Investors of Class Action Filing Involving Medpace Holdings, Inc. – MEDP
NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ:MEDP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Medpace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until June 8, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Medpace securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On February 9, 2026, Medpace released fourth quarter 2025 earnings results, revealing a book-to-bill ratio of 1.04, well below Medpace's guidance.
On this news, Medpace's stock price fell $84.30 per share, or 15.9%, to close at $446.05 per share on February 10, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP